MedTrace Logo

Study to Learn More About the Physical Activity Level of Patients Suffering From Hemophilia A Treated With Damoctocog Alfa Pegol (LIFE ACTIVE Study)

NCT04091386 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2025-06-15

No results posted yet for this study

Summary

In this study researcher want to learn more about the change of physical activity of hemophilia A patients treated with damoctocog alfa pegol. Patients enrolled in this study will be wearing a small device measuring daily active time. Researcher will compare these physical activity data with patient's clinical data including bleeding events to gain information on how bleeding levels are related to the activity level of the patients.

The study aims to enroll about 80 patients who are at the same time also participating in the HEM-POWR study (NCT03932201) evaluating the effectiveness and safety of damoctocog alfa pegol.

Conditions

Interventions

DRUG

Damoctocog alfa pegol (Jivi, BAY94-9027)

Intervention is given as part of routine medical practice

Sponsors & Collaborators

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-10
Primary Completion
2024-05-07
Completion
2024-07-05

Countries

  • United States
  • Belgium
  • Canada
  • Italy
  • Slovenia
  • Spain
  • Taiwan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04091386 on ClinicalTrials.gov